한글목차

후천성 희귀 혈액질환 치료제 세계 시장, 2030년까지 124억 달러에 달할 것으로 전망

2023년 85억 달러로 추정되는 후천성 희귀 혈액질환 치료제 세계 시장은 2023-2030년 분석 기간 동안 연평균 5.4% 성장하여 2030년에는 124억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 면역글로불린 수액 요법은 CAGR 5.1%를 기록하여 분석 기간 종료 시점에 46억 달러에 도달할 것으로 예상됩니다. 재조합 인자 치료 부문은 분석 기간 동안 CAGR 7.1%의 성장률을 기록할 것으로 추정됩니다.

미국 시장 23억 달러로 추정, 중국은 CAGR 8.8%로 성장 전망

미국의 후천성 희귀 혈액질환 치료제 시장은 2023년 23억 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년 분석 기간 동안 8.8%의 CAGR을 기록하여 2030년에는 26억 달러 규모에 달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 2.2%와 5.5%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 연평균 3.3%의 성장률을 보일 것으로 예상됩니다.

세계 후천성 희귀 혈액질환 치료제 시장 - 주요 동향 및 촉진요인 요약

재생불량성 빈혈, 발작성 야간 혈색소뇨증(PNH), 골수이형성증후군(MDS) 등 후천성 희귀 혈액질환은 희귀 혈액질환군을 대표하는 질환입니다. 이들 질환의 특징은 유병률이 낮고 진단과 치료가 모두 복잡하다는 점입니다. 이들 질환의 치료제는 그 희귀성으로 인해 '희귀의약품'으로 간주되며, 정부의 지원 없이 비상장 기업이 치료제를 개발할 경제적 인센티브가 없습니다.

최근 후천성 희귀 혈액질환 치료의 발전은 질환의 진행에 관여하는 특정 경로에 대한 표적치료에 초점을 맞추고 있습니다. 예를 들어, 보체 억제제의 도입으로 PNH의 치료는 혈구 파괴를 억제하고, 삶의 질을 개선하며, 수혈의 필요성을 감소시키는 등 획기적인 변화를 가져왔습니다. 골수이형성증후군(MDS)의 경우, 질병의 후성유전학적 상황을 변화시키는 새로운 약물 요법이 증상 관리와 생존율 연장에 대한 가능성을 보여주고 있습니다.

후천성 희귀 혈액질환 치료제 시장의 성장은 연구개발 활동의 활성화, 조기에 정확한 진단을 가능하게 하는 유전자 검사의 발전, 더 나은 질병 관리를 위한 유망한 약물의 강력한 파이프라인에 의해 이루어지고 있습니다. 또한, 특허 독점 기간 연장 및 세제 혜택과 같은 정부의 우대 정책은 희귀질환 치료제에 대한 제약사들의 연구 투자를 촉진하고 있습니다. 임상시험의 국제 협력도 확대되고 있으며, 이는 종합적인 데이터 수집과 새로운 치료법의 승인 절차의 신속화를 목표로 하고 있습니다. 이러한 발전에도 불구하고, 높은 치료 비용과 제한된 환자 수로 인해 이러한 중요한 의약품에 대한 폭넓은 접근성이 여전히 제한되어 있어, 이 복잡한 치료 영역에서 치료 결과를 개선하기 위한 지속적인 혁신과 정책적 지원이 필요함을 강조하고 있습니다.

조사 대상 기업 예시(주목받는 86개 기업)

• Amgen Inc.
• Apellis Pharmaceuticals
• Chartwell Pennsylvania, LP
• CSL Limited
• F. Hoffmann-La Roche Ltd
• FFF Enterprises, Inc.
• KabaFusion
• Novo Nordisk A/S
• Nufactor Inc.
• Option Care Health Inc.
• Optum, Inc.
• Pfizer Inc.
• Sanofi SA
• Soloo Health
• Takeda Pharmaceutical Company Limited;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 성장 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Acquired Orphan Blood Diseases Therapeutics Market to Reach US$12.4 Billion by 2030

The global market for Acquired Orphan Blood Diseases Therapeutics estimated at US$8.5 Billion in the year 2023, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Immunoglobulin Infusion Therapy, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Recombinant Factor Therapy segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.8% CAGR

The Acquired Orphan Blood Diseases Therapeutics market in the U.S. is estimated at US$2.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Acquired Orphan Blood Diseases Therapeutics Market - Key Trends and Drivers Summarized

Acquired orphan blood diseases, which include conditions such as aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), and myelodysplastic syndromes (MDS), represent a group of rare hematological disorders. These diseases are characterized by their low prevalence and complexity in both diagnosis and treatment. Therapeutics for these conditions are considered 'orphan drugs' due to the rare nature of the diseases they treat and the lack of financial incentive for private companies to develop treatments without government assistance.

Recent advances in the therapeutics for acquired orphan blood diseases have focused on targeted therapies that address specific pathways involved in disease progression. For example, treatments for PNH have transformed with the introduction of complement inhibitors, which help reduce blood cell destruction, improve quality of life, and decrease the need for blood transfusions. In the case of MDS, new drug therapies that modify the disease's epigenetic landscape have shown promise in managing symptoms and extending survival rates.

The growth in the therapeutics market for acquired orphan blood diseases is driven by increased research and development activities, advancements in genetic testing that facilitate early and accurate diagnosis, and a robust pipeline of drugs that hold promise for better disease management. Additionally, government incentives, including extended patent exclusivity and tax benefits, have encouraged pharmaceutical companies to invest in the research of orphan drugs. International collaborations in clinical trials are also expanding, aiming to gather comprehensive data and accelerate the approval process of new therapies. Despite these advancements, challenges such as high treatment costs and limited patient populations continue to impede broader access to these crucial medications, highlighting the need for continued innovation and policy support to improve treatment outcomes in this complex therapeutic area.

Select Competitors (Total 86 Featured) -

• Amgen Inc.
• Apellis Pharmaceuticals
• Chartwell Pennsylvania, LP
• CSL Limited
• F. Hoffmann-La Roche Ltd
• FFF Enterprises, Inc.
• KabaFusion
• Novo Nordisk A/S
• Nufactor Inc.
• Option Care Health Inc.
• Optum, Inc.
• Pfizer Inc.
• Sanofi SA
• Soleo Health
• Takeda Pharmaceutical Company Limited;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Acquired Orphan Blood Diseases Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Awareness of Orphan Blood Diseases
  • Advances in Genetic and Molecular Research
  • Growing Investment in Rare Disease Drug Development
  • Rising Number of Clinical Trials and Research Studies
  • Development of Novel Therapeutics and Gene Therapies
  • Patient Advocacy and Support Organizations
  • Expansion of Specialized Treatment Centers
  • Technological Innovations in Diagnostic Tools
  • Growth of Personalized Medicine Approaches
  • Government Funding and Grants for Rare Diseases
  • Increasing Demand for Targeted Therapies
  • Advances in Hematopoietic Stem Cell Transplantation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Acquired Orphan Blood Diseases Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunoglobulin Infusion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunoglobulin Infusion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Immunoglobulin Infusion Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Factor Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Recombinant Factor Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Recombinant Factor Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Activated Prothrombin Complex Concentrate Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Activated Prothrombin Complex Concentrate Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Activated Prothrombin Complex Concentrate Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Thrombopoietin Receptor Agonists Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Thrombopoietin Receptor Agonists Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Thrombopoietin Receptor Agonists Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Myelodysplastic Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Myelodysplastic Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Myelodysplastic Syndrome Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Acquired Hemophilia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Acquired Hemophilia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Acquired Hemophilia Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Acquired Agranulocytosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Acquired Agranulocytosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Acquired Agranulocytosis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Acquired Von Willebrand Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Acquired Von Willebrand Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Acquired Von Willebrand Syndrome Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• JAPAN
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• CHINA
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: China 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: China 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: China 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• EUROPE
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• FRANCE
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: France 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: France 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: France 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• GERMANY
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Germany 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Germany 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Italy 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Italy 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: UK 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: UK 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Spain 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Spain 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Russia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Russia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Rest of Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Rest of Europe 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Australia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Australia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• INDIA
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: India 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: India 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: India 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: South Korea 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: South Korea 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Argentina 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Argentina 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Brazil 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Brazil 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Mexico 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Mexico 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Rest of Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Rest of Latin America 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Iran 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Iran 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Israel 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Israel 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Saudi Arabia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Saudi Arabia 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: UAE 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: UAE 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Rest of Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Rest of Middle East 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• AFRICA
  • Acquired Orphan Blood Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Immunoglobulin Infusion Therapy, Recombinant Factor Therapy, Activated Prothrombin Complex Concentrate Therapy, Thrombopoietin Receptor Agonists Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 316: Africa 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Myelodysplastic Syndrome Disease, Other Disease Types, Acquired Hemophilia Disease, Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease, Acquired Agranulocytosis Disease and Acquired Von Willebrand Syndrome Disease for the Years 2014, 2024 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 319: Africa 16-Year Perspective for Acquired Orphan Blood Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION